14^th Biosimilar Market Report

Q3 2026

We are pleased to present the 14th edition of our Biosimilar Market Report, offering our latest analysis of US pricing and market share dynamics across key biosimilar markets.

The US drug pricing landscape continues to shift toward greater transparency and accountability. Following our Q1 coverage of PBM reform, this edition turns to another policy development: the ongoing 340B Drug Pricing Program reform discussions. Health Resources and Services Administration (HRSA) is considering a transition from the current upfront discount model to a rebate-based model, which would introduce new reporting requirements and alter how 340B discounts flow between manufacturers and covered entities.

In this quarter's deep-dive section, we examine the 340B reform landscape and its potential implications for the biosimilar market. We explore how changes to 340B economics may influence biosimilar adoption dynamics and discuss both the opportunities and mitigating factors that biosimilar stakeholders should consider.

Thank you for your ongoing engagement with our reports. Our report continues to offer an in-depth perspective on current market trends, challenges, and strategic opportunities for stakeholders navigating this rapidly changing landscape.

© 2026 Samsung Bioepis Co., Ltd. All Rights Reserved. 07/2026.